Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

COMPANY OF THE WEEK

Saturday 16 May 1998 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

BTP shares rose 5 per cent last week on optimism over New York- based Pfizer's Viagra impotence pill, for which the British chemical company makes an ingredient.

BTP, which produces a range of specialty chemicals, including disinfectants, agrochemicals and brewing agents, jumped 24 pence to 523.5. It has risen 24 per cent during the past 10 trading days.

Sales of Viagra, which was introduced a month ago, are likely to top $1bn in the first 12 months, and may reach as much as $2bn in 1999, analysts have estimated.

"It's such a powerful story in terms of sentiment. You're going to get a lot of publicity for Viagra," said Jeremy Chantry, an analyst at Credit Lyonnais Securities.

Mr Chantry had a "buy" stance on the company even before news of Viagra's potential was released.

Mr Chantry said that sales related to the pill could account for about 3 per cent of BTP's profit in a couple of years.

Traders and investors said Credit Suisse First Boston analysts repeated their "buy" stance on the stock and set a price target of 615p.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in